Table 2.
Baseline circulating tumor cells (CTC) count, prostate specific antigen (PSA) and characteristics of the bone metastases assessed by whole body diffusion weighted imaging (WB-DWI) with the different delineation techniques in responders and non-responder patients.
Q1: 1st quartile, Q3: 3rd quartile
| Responders | Non-responders | Mann-Whitney p-value | |||||
|---|---|---|---|---|---|---|---|
| N | Median (Q1, Q3) | Min, max | N | Median (Q1, Q3) | Min, max | ||
| Clinical characteristics | |||||||
| CTC (number/7.5ml) | 6 | 63 (8, 102) | 3, 105 | 15 | 46 (8, 104) | 6, 187 | 0.845 |
| PSA (ng/ml) | 6 | 868 (34, 1847) | 28, 2949 | 15 | 381 (146, 456) | 19, 1505 | 0.350 |
| Axial skeleton DWI signal abnormality | |||||||
| Volume (L) | 6 | 0.83 (0.17, 1.01) | 0.16, 1.31 | 15 | 0.44 (0.16, 0.79) | 0.01, 1.07 | 0.243 |
| Median ADC (x10-6 mm2/s) | 6 | 847 (775, 921) | 693, 1121 | 15 | 748 (726, 915) | 684, 1023 | 0.312 |
| Up to 5 target lesions | |||||||
| Volume (L) | 6 | 0.05 (0.04, 0.06) | 0.04, 0.09 | 15 | 0.05 (0.02, 0.12) | 0.01, 0.52 | 0.876 |
| Median ADC (x10-6 mm2/s) | 6 | 859 (814, 900) | 606, 1712 | 15 | 737 (695, 865) | 624, 1017 | 0.312 |
| Central slice 5 target lesions | |||||||
| Diameter (mm) | 2 | 15.3 (14.3, 16.3) | 14.3, 16.3 | 7 | 11.6 (7.5, 13.1) | 2.8, 20.2 | 0.143 |
| Median ADC (x10-6 mm2/s) | 6 | 941 (867, 1002) | 555, 1263 | 15 | 743 (673, 852) | 575, 1083 | 0.073 |
| Entire axial skeleton | |||||||
| Median ADC (x10-6 mm2/s) | 6 | 808 (650, 1093) | 614, 1182 | 15 | 805 (751, 1002) | 722, 1039 | 0.938 |